Publications

Immunogenomic characterization of biliary tract cancers: Biomarker enrichment for benefit to immune checkpoint blockade.

W Park, F Keane, C Bandlamudi, M Donoghue, P Tallón de Lara, ...

Improving understanding of pancreatic cancer among patients using an animated patient’s guide to benefit informed decisions and health outcomes.

S Munigala, EM O'Reilly, DE Bakelman, J Holt, AH Ko, N Searle, A Gelrud

Incidence of Pancreatic Cancer by Age and Sex in the US From 2000 to 2018

F Keane, M Du, EM O’Reilly

Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma

McIntyre CA, Cohen NA, Goldman DA, Gonen M, Sadot E, O'Reilly EM, Varghese AM, Yu KH, et al.

Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma

Zheng-Lin B, Rainone M, Varghese AM, Yu KH, Park W, Berger M, Mehine M, Chou J, et al.

Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of “Second Hit” in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma: B …

B Zheng-Lin, M Rainone, AM Varghese, KH Yu, W Park, M Berger, ...

Mo1225: ACUTE PANCREATITIS CAN UNMASK UNDERLYING PANCREATIC ADENOCARCINOMA IN PATIENTS WITH UNCLEAR ETIOLOGY OF PANCREATITIS: A MULTICENTER ELECTRONIC HEALTH RESEARCH NETWORK …

RR Singh, A Klein, EM O'Reilly

Molecular characterization of gallbladder cancer

NA Giraldo, A Mohanty, C Vanderbilt, R Brannon, R Benayed, E Vakiani, ...

Multi-institutional comparison of ablative radiation therapy in 5 versus 15-25 fractions for locally advanced pancreatic cancer

M Reyngold, E O'Reilly, R Herrera, A Kaiser, M Zinovoy, PB Romesser, ...

Neo‐adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma

S Temraz, F Nassar, MS Hammoud, D Mukherji, EM O'Reilly, H Dbouk, ...

Neoadjuvant radiotherapy after (m) FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: a TAPS consortium study

QP Janssen, JL van Dam, LR Prakash, D Doppenberg, CH Crane, ...

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, et al.

P-22 phase III study (daNIS-2) of the anti–TGF-β monoclonal antibody NIS793 with nab-paclitaxel/gemcitabine vs nab-paclitaxel/gemcitabine alone in patients with first-line …

E O'Reilly, T Golan, M Ikeda, M Milella, J Taieb, Z Wainberg, L Wang, ...

Pancreatic cancer: Cutaneous metastases, clinical descriptors and outcomes.

EM O'Reilly

Persistent Disparities in Treatment and Survival for Patients with Pancreatic Cancer Despite Insurance Expansion Policies

L Saadat, J Chou, M Gonen, K Soares, V Balachandran, TP Kingham, ...

Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.

RK Kelley, E Van Cutsem, MS Lee, I Wolf, M Fakih, J de Vos-Geelen, ...

Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma.

VP Balachandran, LA Rojas, Z Sethna, K Soares, E Derhovanessian, ...

Phase III study (daNIS-2) of the anti–TGF-β monoclonal antibody (mAb) NIS793 with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic …

EM O'Reilly, T Golan, M Ikeda, M Milella, J Taieb, ZA Wainberg, LW Wang, ...

Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)

Nixon AB, Sibley AB, Liu Y, Hatch AJ, Jiang C, Mulkey F, Starr MD, Brady JC, et al.

Precision approaches to pancreatic cancer therapy: what now and what next?

F Keane, W Park, EM O’Reilly

Precision Medicine and Immunotherapy in GI Cancers

O'Reilly EM, Ko AH

Radiation Therapy (RT) Quality Assurance (QA) Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus Hypofractionated Radiation Therapy for Borderline …

L Tchelebi, KS Smith, Q Shi, T Fitzgerald, MD Chuong, T Zemla, E O'Reilly, ...

Real-world clinical outcomes of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens: Impact of prior irinotecan …

KH Yu, P Cockrum, A Surinach, N Lamarre, S Wang, EM O'Reilly

Salvage ablative radiation therapy for loco-regionally recurrent pancreatic ductal adenocarcinoma following surgical resection.

V Ng, M Zinovoy, C Hajj, PB Romesser, AJC Wu, JJ Cuaron, WR Jarnagin, ...

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, et al.

Stereotactic ablative radiation for pancreatic cancer on a 1.5 áTelsa magnetic resonance-linac system

KR Tringale, N Tyagi, PB Romesser, A Wu, EM O'Reilly, AM Varghese, ...

Supporting Patients with Cancer after Dobbs v. Jackson Women’s Health Organization

AG Shuman, MS Aapro, B Anderson, K Arbour, PC Barata, A Bardia, ...

Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405

Lipsyc-Sharf M, Zhang S, Ou FS, Ma C, McCleary NJ, Niedzwiecki D, Chang IW, Lenz HJ, et al.

The frequency of second primary malignancies and colonic polyps in Lynch syndrome with MSI tumors following immune checkpoint blockade.

E Harrold, Z Patel, A Maio, A Cercek, R Yaeger, NH Segal, DL Reidy, ...

The lung pro-thrombotic niche drives cancer-associated thromboembolism and metastasis via extracellular vesicle ITGB2.

S Lucotti, Y Ogitani, CM Kenific, L Bojmar, M Cioffi, P Lauritzen, H Molina, ...

The lung pro-thrombotic niche drives cancer-associated thromboembolism via exosomal ITGB2

S Lucotti, Y Ogitani, CM Kenific, L Bojmar, M Cioffi, P Lauritzen, H Molina, ...

Timing of onset of systemic treatment in asymptomatic patients with metastatic pancreatic cancer: An international expert survey and case-vignette study.

S Augustinus, HWM Van Laarhoven, GA Cirkel, JW de Groot, ...

Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma

TB de Castria, DN Khalil, JJ Harding, EM O’Reilly, GK Abou-Alfa

Venous Thromboprophylaxis in Surgical Oncology Patients: The Importance of Risk Assessment in the Context of Limited Evidence

Snyder RA, O'Reilly EM

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

Schram AM, Odintsov I, Espinosa-Cotton M, Khodos I, Sisso WJ, Mattar MS, Lui AJW, Vojnic M, et al.

Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.

W Park, EM O'Reilly, J Furuse, CP Li, DY Oh, R Garcia-Carbonero, G Roth, ...

1467P POLO: Long-term safety and tolerability of olaparib for patients with a germline BRCA mutation and metastatic pancreatic cancer

D Arnold, T Golan, P Hammel, M Reni, E Van Cutsem, TM Mercade, ...

1468P POLO: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer

T Golan, P Hammel, M Reni, E Van Cutsem, TM Mercade, MJ Hall, ...

343 Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic …

D Maurer, JX Yu, K Sklodowski, M Tognetti, L Reiter, R Bruderer, ...

A Review of Pancreatic Cancer-Reply

Park W, Chawla A, O'Reilly EM

Abstract No. 86 Treatment of pancreatic cancer by intra-arterial injection of an emulsion of lipiodol and bumetanide (an anti-glycolytic drug) in a transgenic mutated pig model …

H Yarmohammadi, A Elsakka, F Nurili, A Maxwell, F Ridouani, E Ziv, ...

Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.

MHG Katz, Q Shi, JP Meyers, JM Herman, M Choung, BM Wolpin, ...

Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO)+ sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).

IH El Dika, SM Geyer, AB Nixon, F Innocenti, Q Shi, SB Jacobson, ...

Assessment of ADI-PEG 20 and modified FOLFOX6 in advanced hepatocellular carcinoma patients: Results of an international, single-arm, phase 2 study

JJ Harding, TS Yang, YY Chen, YH Feng, CJ Yen, CL Ho, WT Huang, ...

Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study

Harding JJ, Yang TS, Chen YY, Feng YH, Yen CJ, Ho CL, Huang WT, El Dika I, et al.

Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer

Reyngold M, O'Reilly EM, Varghese AM, Fiasconaro M, Zinovoy M, … Park W, …

Baseline level and early on-treatment clearance of circulating mutant KRAS in metastatic pancreatic ductal adenocarcinoma treated with chemotherapy with or …

JE Till, A Abdalla, N Bhagwat, TA Black, Z Wang, SS Yee, PF Gherardini, ...

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label …

MH O'Hara, EM O'Reilly, G Varadhachary, RA Wolff, ZA Wainberg, AH Ko, ...

Clarity Plus Confidence: Leveraging eConsent to Assess Participant Agency in the Consent Process

MR O'Shea, M Buckley, J Wang, J Galle, M Lin, M Koch, J Lengfellner, ...

Clinical trials of systemic chemotherapy for resectable pancreatic cancer: a review

MN Mavros, D Moris, PJ Karanicolas, MHG Katz, EM O’Reilly, TM Pawlik